Group 1 - The U.S. FDA approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability [1] - In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications [1] - Following the announcement, Liquidia shares fell 5.2% to trade at $14.80 [1] Group 2 - Wells Fargo analyst Tiago Fauth maintained an Overweight rating on Liquidia and raised the price target from $20 to $23 [6] - HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating and raised the price target from $29 to $35 [6] - Needham analyst Serge Belanger reiterated a Buy rating and maintained a $25 price target [6]

Company Overview - Liquidia Technologies, Inc. (LQDA) shares increased by 13.2% to close at $15.83, with notable trading volume compared to typical sessions, following a 1.1% loss over the past four weeks [1][2] Recent Developments - The U.S. District Court for the District of Columbia dismissed a cross-claim by United Therapeutics challenging Liquidia's amendment to its new drug application for Yutrepia, which now includes treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] Financial Expectations - Liquidia is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year increase of 22.2%, with revenues projected at $3.31 million, up 11.4% from the previous year [3] - The consensus EPS estimate for Liquidia has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Liquidia Technologies operates within the Zacks Medical - Biomedical and Genetics industry, where CRISPR Therapeutics AG (CRSP) also competes, having closed 1.4% higher at $38.25 and showing a 15.5% return over the past month [4]